Intelliject, Inc., a Richmond, Virginia-based specialty pharmaceutical company develping drug/device combination products, has entered into a $15m debt facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC).
The company intends to use the funding to accelerate the development of its pipeline products with final preparation for the launch of its lead product, e-cue™, in North America through its partner, Sanofi.
Led by Spencer Williamson, President and CEO, Intelliject combines an established drug with an innovative delivery platform with the goal of achieving superiority, patient preference and cost effectiveness.
FinSMEs
29/05/2012